We are global leader in the laboratory diagnostics market, specializing in the immunodiagnostics and molecular diagnostics segments. For over 50 years our Group has been developing, producing and commercializing diagnostic tests: we support clinical laboratory needs and activities, providing solutions that are reliable, innovative, fully automated and standardized. We continually invest in Research & Development, using our own distinctive expertise in the field to deliver a high level of innovation.
Group Websites
Clinical Areas
We offer the broadest range of specialty tests available in the immunodiagnostics market.
Discover All Areas
Discover Our Menu
LIAISON® XS
All our technology in a new dimension.
LIAISON® XS delivers a high technology solution for immunochemistry tests that allows laboratories to improve efficiency and clinical effectiveness for routine and specialty testing.
Discover All Systems
Worldwide Presence
Our Group consists of 22 branches with offices across 5 continents and manufacturing premises producing its tests in 5 sites around the world.
Where we are
News
26/10/2020
DiaSorin launches with CE mark the LIAISON® SARS-CoV-2 Ag, a new high-throughput antigen test for COVID-19 detection in symptomatic patients.
Read the press release
07/04/2020
DiaSorin announces the launch of a fully automated serology test to detect antibodies against Sars-CoV-2 in Covid-19 patients within the end of April 2020
Read the press release
20/03/2020
DiaSorin Molecular LLC, a division of DiaSorin S.p.A., has received the Emergency Use Authorization (EUA) from the FDA for their Simplexa™ COVID-19 Direct kit.
Read the press release
06/02/2020
MEDLAB CONGRESS - Visit our booth #Z5.C30 and discover our new solution. Medlab Middle East, Dubai World Trade Centre